Northwest Biotherapeutics, Inc. (NWBO) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Northwest Biotherapeutics is a biotech company focused on developing immunotherapy products to treat cancers more effectively than current treatments, eliminating toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. NBWO’s lead program is a 312-patient phase 3 trial in newly diagnosed glioblastoma multiforme (GBM), the most aggressive and lethal form of brain cancer. For more information visit the company’s Web site at www.nwbio.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
